Your browser doesn't support javascript.
loading
Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study.
Uittenboogaard, Aniek; van de Velde, Mirjam; van de Heijden, Lisa; Mukuhi, Leah; de Vries, Niels; Langat, Sandra; Olbara, Gilbert; Huitema, Alwin D R; Vik, Terry; Kaspers, Gertjan; Njuguna, Festus.
Afiliación
  • Uittenboogaard A; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van de Velde M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van de Heijden L; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Mukuhi L; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Vries N; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.
  • Langat S; Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
  • Olbara G; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Huitema ADR; Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
  • Vik T; Department of Child Health and Paediatrics, Moi University/Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Kaspers G; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Njuguna F; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pediatr Blood Cancer ; 71(9): e31160, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38956809
ABSTRACT
The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vincristina / Estudios de Factibilidad / Enfermedades del Sistema Nervioso Periférico Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vincristina / Estudios de Factibilidad / Enfermedades del Sistema Nervioso Periférico Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos